( five patients had detectable CsA levels...)Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis,Health

These results are presented at the occasion of a Symposium chaired by Pr BenEzra, lead coordinator of the study.

About Novagali Pharma Vekacia(R):

Vekacia(R) is a Cyclosporine A ophthalmic product intended for patients suffering from vernal keratoconjunctivitis. Vekacia(R) is a proprietary cationic emulsion enabling an efficient and unmatched-level drug absorption in tissues of the eye leading to optimal therapeutic efficacy.

About Novagali Pharma: www.novagali.com

Novagali Pharma SA is an emerging ophthalmic pharmaceutical company based in the Genopole biocluster in Evry, France, that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis; Cationorm(R), a CE marking product for dry eye relief; and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, the firm has raised a total amount of Euro 44 million in 3 series of financing and currently has 38 employees.

    Contacts Presse

    Novagali

    VP HR & Communication

    Genevieve Garrigos

    +33-1-69-87-40-20

    


    Euro RSCG

    Estelle Griffe

    +33-1-58-47-95-25 / +33-6-23-75-09-23

    

Nova Gali Pharma

CONTACT: Contacts Presse: Novagali, VP HR & Communication, GenevieveGarrigos, +33-1-69-87-40-20, ; Euro RSCG,Estelle Griffe, +33-1-58-4
'"/>